We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

41 hedge funds and large institutions have $1.09M invested in Oncolytics Biotech in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.96% less ownership

Funds ownership: 2.2% → 1.23% (-0.96%)

9% less funds holding

Funds holding: 45 → 41 (-4)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

36% less capital invested

Capital invested by funds: $1.69M → $1.09M (-$602K)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
41
Holders Change
-4
Holders Change %
-8.89%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
11
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fifth Third Bancorp
Fifth Third Bancorp
Ohio
+$16.8K
2
CIBC World Market
CIBC World Market
Ontario, Canada
+$14K
3
IAIM
International Assets Investment Management
Florida
+$11.4K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$8.74K
5
Osaic Holdings
Osaic Holdings
Arizona
+$8.48K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$352K
2
Citadel Advisors
Citadel Advisors
Florida
-$140K
3
ARC
Advisor Resource Council
Texas
-$139K
4
JP Morgan Chase
JP Morgan Chase
New York
-$50K
5
Morgan Stanley
Morgan Stanley
New York
-$47.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
IAIM
1
International Assets Investment Management
Florida
$285K +$11.4K +6,815 +4%
CIBC World Market
2
CIBC World Market
Ontario, Canada
$109K +$14K +8,324 +14%
Morgan Stanley
3
Morgan Stanley
New York
$94K -$47.3K -28,185 -32%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$71K +$5.99K +3,570 +9%
LFCM
5
Long Focus Capital Management
Puerto Rico
$63K – – –
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$58K +$8.74K +5,207 +17%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$54K – – –
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$53K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$40K -$352K -209,978 -89%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$38K -$30.4K -18,100 -43%
LPL Financial
11
LPL Financial
California
$34K +$1.68K +1,000 +5%
BAM
12
Brave Asset Management
New Jersey
$32K – – –
Comerica Bank
13
Comerica Bank
Texas
$22K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$18K -$140K -83,696 -88%
BCV
15
Banque Cantonale Vaudoise
Switzerland
$18K – – –
Fifth Third Bancorp
16
Fifth Third Bancorp
Ohio
$17K +$16.8K +10,000 +1,000%
Osaic Holdings
17
Osaic Holdings
Arizona
$11K +$8.48K +5,055 +171%
CMA
18
Cedar Mountain Advisors
Oregon
$9K – – –
DI
19
Disciplined Investments
Oklahoma
$8K – – –
Rockefeller Capital Management
20
Rockefeller Capital Management
New York
$8K – – –
ZB
21
Zions Bancorporation
Utah
$8K – – –
Wells Fargo
22
Wells Fargo
California
$7K +$4.03K +2,400 +126%
National Bank of Canada
23
National Bank of Canada
Quebec, Canada
$6K -$1.68K -1,000 -22%
FDCDDQ
24
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5.38K – – –
Bank of America
25
Bank of America
North Carolina
$5K -$20.1K -12,000 -80%
1
2

ONCY Hedge Fund Activity: Q1 2022 in Review

41 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q1 2022, worth a combined $1.09M — down 36% from $1.69M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ONCY and 5 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Fifth Third Bancorp, adding an estimated $16.8K. The largest seller was Renaissance Technologies, cutting an estimated $352K.

  • 41 institutional investors held Oncolytics Biotech (ONCY) as of Q1 2022, down from 45 in Q4 2021.
  • Funds reported $1.09M of Oncolytics Biotech stock for Q1 2022, down 36% quarter-over-quarter.
  • 5 funds opened new Oncolytics Biotech positions in Q1 2022 and 8 closed out, a net change of -3 holders.
  • The largest Oncolytics Biotech buyer in Q1 2022 was Fifth Third Bancorp, an estimated $16.8K added.
  • The largest Oncolytics Biotech seller in Q1 2022 was Renaissance Technologies, an estimated $352K sold.

Based on aggregated 13F filings for Q1 2022.